124 related articles for article (PubMed ID: 19609487)
1. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
3. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
4. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
Kaneko A; Kida D; Saito K; Tsukamoto M; Sato T
Rheumatol Int; 2012 Nov; 32(11):3631-7. PubMed ID: 22127466
[TBL] [Abstract][Full Text] [Related]
5. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
6. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
7. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
8. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
[TBL] [Abstract][Full Text] [Related]
10. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
Nishimoto N; Takagi N
Mod Rheumatol; 2010 Dec; 20(6):539-47. PubMed ID: 20617358
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
13. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
[TBL] [Abstract][Full Text] [Related]
14. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
Matsuno H
Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
[TBL] [Abstract][Full Text] [Related]
15. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
[TBL] [Abstract][Full Text] [Related]
16. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Ueki Y; Migita K; Mizokami A; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):370-4. PubMed ID: 21240618
[TBL] [Abstract][Full Text] [Related]
17. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
[TBL] [Abstract][Full Text] [Related]
19. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
20. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
